When the rich and powerful try to work together to become even bigger, backlash can be expected. German pharmaceutical giant Bayer’s agreed acquisition of American agricultural biochemical company Monsanto for $66 billion (a $128/share valuation) was no exception. The impending Bayer-Monsanto merger has already acquired negative reviews, in part due to antitrust concerns and in […]